Japan

Japan has a conservative, prohibition-first framework for classical psychedelics. In practice, psilocybin, MDMA, DMT and related compounds are treated as controlled/narcotic or designated substances, with no routine authorised medical access outside approved research pathways.

Ask Blossom about this country

Data updated May 18, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inJapan.

1
Japan's psychedelic field appears small and clinically oriented, with the clearest published activity concentrated in treatment-resistant depression rather than broader indications.
2
The presence of both psilocybin and esketamine trial registrations suggests research interest in novel depression treatments, but this should not be read as a signal of regulatory approval.
3
MHLW's current drug-control materials indicate continuing active oversight of narcotics and designated substances, consistent with a restrictive access environment.
4
Ketamine is the main near-term clinical access comparator in Japan because it is already embedded in conventional medical practice, whereas classical psychedelics are still confined to study settings.
5
Blossom's linked-trial footprint of one active TRD study fits the published registry picture: Japan has measurable but limited psychedelic-adjacent research activity, rather than a broad clinical market.

Research and Access Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Japan, including 1 active study.

Active trials: 1
Total trials: 1
Stakeholders: 4
Events: 0

Top Compounds

Linked country trials do not show a leading compound yet.

Active Trial Preview

View all trials →

A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single subcutaneous MIJ821 injection in addition to standard of care in participants with treatment-resistant depressionRecruiting - II

Medical Access

Japan maintains a conservative, prohibition-focused legal framework for classical psychedelic compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ayahuasca, ibogaine and 2C-X) - these are controlled under national drug control statutes and have no authorised medical use outside approved research. Ketamine is an established, licensed anesthetic and analgesic in Japan and is available via the medical system; psychiatric/off-label use for depression is conducted as clinical care or research with limited reimbursement. Esketamine (the S-enantiomer...

View trials→View stakeholders→Open access guide→

Regulatory Status

Classical psychedelics remain tightly controlled under Japan's narcotics and psychotropics framework, and current MHLW materials continue to list controlled substances and enforcement measures rather than any approved psychedelic treatment route. Ketamine is an established licensed medicine, and Japan has registered clinical research on ketamine, psilocybin and esketamine for depression; however, publicly available sources do not support routine national access or reimbursement for psychedelic therapies, so the practical status for psychedelics should be treated as research-only unless a specific protocol or approval is confirmed.